

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

ETAS ID: TM793126

|   |  |                       |  |
|---|--|-----------------------|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                                       |                       |  |
| <b>NATURE OF CONVEYANCE:</b>  | SECURITY INTEREST                                    |                       |  |
| <b>CONVEYING PARTY DATA</b>   |  |                       |  |
| <b>Name</b>   | <b>Formerly</b>                                      | <b>Execution Date</b> | <b>Entity Type</b>                       |
| Organix Chemistry Solutions LLC   |  | 03/07/2023            | Limited Liability Company: MASSACHUSETTS |
| <b>RECEIVING PARTY DATA</b>   |  |                       |  |
| <b>Name:</b>  | Wilmington Trust (London) Limited, as Security Agent |                       |  |
| <b>Street Address:</b>  | Third Floor, 1 King's Arms Yard                      |                       |  |
| <b>City:</b>  | London   |                       |  |
| <b>State/Country:</b>   | UNITED KINGDOM                                       |                       |  |
| <b>Postal Code:</b>   | EC2R 7AF   |                       |  |
| <b>Entity Type:</b>   | Limited Corporation: UNITED KINGDOM                  |                       |  |
| <b>PROPERTY NUMBERS Total: 2</b>  |  |                       |  |
| <b>Property Type</b>  | <b>Number</b>  | <b>Word Mark</b>      |  |
| <b>Serial Number:</b>   | 86768762   | POWERPLANT            |  |
| <b>Registration Number:</b>   | 3931304  | REPEET                |  |
| <b>CORRESPONDENCE DATA</b>  |  |                       |  |
| <b>Fax Number:</b>  |  |                       |  |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |                       |  |
| <b>Phone:</b>   | 8004945225   |                       |  |
| <b>Email:</b>   | ipteam@cogencyglobal.com                             |                       |  |
| <b>Correspondent Name:</b>  | JAY DASILVA  |                       |  |
| <b>Address Line 1:</b>  | 1025 CONNECTICUT AVE., NW, STE. 712                  |                       |  |
| <b>Address Line 2:</b>  | COGENCY GLOBAL INC.                                  |                       |  |
| <b>Address Line 4:</b>  | WASHINGTON, D.C. 20036                               |                       |  |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 1932467 TM   |                       |  |
| <b>NAME OF SUBMITTER:</b>   | Jonathan Larson                                      |                       |  |
| <b>SIGNATURE:</b>   | /Jonathan Larson/                                    |                       |  |
| <b>DATE SIGNED:</b>   | 03/09/2023   |                       |  |
| <b>Total Attachments: 8</b>   |  |                       |  |
| source=01. Symeres - New York IP Security Agreement [Trademarks]#page2.tif  |  |                       |  |
| source=01. Symeres - New York IP Security Agreement [Trademarks]#page3.tif  |  |                       |  |

OP \$65.00 86768762

source=01. Symeres - New York IP Security Agreement [Trademarks]#page4.tif  
source=01. Symeres - New York IP Security Agreement [Trademarks]#page5.tif  
source=01. Symeres - New York IP Security Agreement [Trademarks]#page6.tif  
source=01. Symeres - New York IP Security Agreement [Trademarks]#page7.tif  
source=01. Symeres - New York IP Security Agreement [Trademarks]#page8.tif  
source=01. Symeres - New York IP Security Agreement [Trademarks]#page9.tif

# **INTELLECTUAL PROPERTY SECURITY AGREEMENT**

March 7, 2023

between

**ORGANIX CHEMISTRY SOLUTIONS LLC**

as Security Provider

and

**WILMINGTON TRUST (LONDON) LIMITED**

as Security Agent

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (the **Intellectual Property Security Agreement**) dated March 7, 2023, is made by and between ORGANIX CHEMISTRY SOLUTIONS LLC, as security provider (the **Security Provider**) and WILMINGTON TRUST (LONDON) LIMITED, as security agent and security trustee for the Secured Parties (as defined in the Intercreditor Agreement referred to below) (the **Security Agent**).

WHEREAS, the Security Provider has entered into an Accession Deed dated March 7, 2023, pursuant to which they have acceded to (i) the Intercreditor Agreement dated December 23, 2019 (as further amended and/or restated the **Intercreditor Agreement**) between, among others, Drug Discovery Services B.V. as parent, the entities listed therein as Senior Lenders and the Security Agent and (ii) the senior facilities agreement dated December 23, 2019 between, among others, Drug Discovery Services B.V. as parent, the companies listed therein as original guarantors and the Security Agent (as further amended, the **Facilities Agreement**, together with the Intercreditor Agreement, the **Loan Documents**).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders under the Loan Documents, the Security Provider has executed and delivered to the Security Agent that certain Security Agreement dated March 7, 2023 (the **Security Agreement**), made by and among, the Security Provider, Organix LLC, as security provider, MerchachemSyncom US, Inc., as security provider and the Security Agent.

WHEREAS, under the terms of the Security Agreement, the Security Provider has granted to the Security Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Security Provider, and has agreed to execute and deliver this Intellectual Property Security Agreement for recording with the United States Patent and Trademark Office and the United States Copyright Office. Capitalized terms used herein but not otherwise defined have the meanings given to such terms in the Facilities Agreement, the Intercreditor Agreement or the Security Agreement, as applicable.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Grant of Security.** The Security Provider hereby pledges and grants to the Security Agent for the benefit of the Secured Parties a security interest in and to all of the right, title, and interest of such Security Provider in, to, and under the following (the **IP Collateral**):
  - (a) the patents and patent applications set forth in Schedule 1 hereto and all reissues, divisions, continuations, continuations-in-part, renewals, extensions, and reexaminations thereof and amendments thereto (the **Patents**);
  - (b) the trademark registrations and applications set forth in Schedule 2 hereto, together with the goodwill connected with the use thereof and symbolized thereby, and all extensions and renewals thereof (the **Trademarks**), excluding only United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant, attachment, or enforcement of a security interest therein would, under applicable federal law, impair the registrability of such applications or the validity or enforceability of registrations issuing from such applications;
  - (c) the copyright registrations, applications, and copyright registrations and applications exclusively licensed to such Security Provider set forth in Schedule 3 hereto, and all extensions and renewals thereof (the **Copyrights**);

- (d) all rights of any kind whatsoever of such Security Provider accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;
  - (e) any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and
  - (f) any and all claims and causes of action with respect to any of the foregoing, whether occurring before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right, but no obligation, to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.
2. Recordation. The Security Provider authorizes the Commissioner for Patents, the Commissioner for Trademarks, the Register of Copyrights, and any other government officials to record and register this Intellectual Property Security Agreement upon request by the Security Agent.
  3. Debt Documents. This Intellectual Property Security Agreement has been entered into pursuant to and in conjunction with the Security Agreement, which is hereby incorporated by reference. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Security Agent with respect to the IP Collateral are as provided by the Facilities Agreement, the Intercreditor Agreement, the Security Agreement, and related documents, and nothing in this Intellectual Property Security Agreement shall be deemed to limit such rights and remedies.
  4. Execution in Counterparts. This Intellectual Property Security Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Intellectual Property Security Agreement by facsimile or in electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this Intellectual Property Security Agreement.
  5. Successors and Assigns. This Intellectual Property Security Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.
  6. Governing Law. This Intellectual Property Security Agreement, the relationship between the Security Provider and the Secured Parties and any claim or dispute (whether sounding in contract, tort, statute or otherwise) relating to this Intellectual Property Security Agreement or that relationship shall be governed by and construed in accordance with law of the State of New York including section 5-1401 of the New York General Obligations Law but excluding any other conflict of law rules that would lead to the application of the law of another jurisdiction. If the law of a jurisdiction other than New York is, under section 1-301(c) of the UCC, mandatorily applicable to the perfection, priority or enforcement of any security interest granted under this Agreement in respect of any particular Collateral, that other law shall apply solely to the matters of perfection, priority or enforcement to which it is mandatorily applicable.

**ORGANIX CHEMISTRY SOLUTIONS LLC,**  
as Security Provider

DocuSigned by:

*Anu Mahadevan*

3B3ACA5D2ED44CC...

By: **Anu Mahadevan**

Title: Chief Executive Officer

**WILMINGTON TRUST (LONDON) LIMITED,**  
as Security Agent

By:

Title:

**WILMINGTON TRUST (LONDON) LIMITED,**  
as Security Agent



By: Antony Girling

Title: Vice President

**SCHEDULES TO INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**SCHEDULE 1**

**PATENTS**

**Patents**

| <b>Title</b>  | <b>Patent Number</b> | <b>Issue Date</b> | <b>Record Owner</b>             |
|---|----------------------|-------------------|---------------------------------|
| Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders | 5493026              | 02/20/1996        | Organix Chemistry Solutions LLC |
| Bridge-substituted tropanes for methods of imaging and therapy  | 5770180              | 06/23/1998        | Organix Chemistry Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport   | 5948933              | 07/11/1997        | Organix Chemistry Solutions LLC |
| Dopamine transporter imaging agent  | 6171576              | 01/09/2001        | Organix Chemistry Solutions LLC |
| Pyrazole cannabinoid agonist and antagonists  | 6509367              | 01/21/2003        | Organix Chemistry Solutions LLC |
| Compounds with high monoamine transporter affinity  | 6525206              | 02/25/2003        | Organix Chemistry Solutions LLC |
| Serotonin transport inhibitors  | 6677338              | 01/13/2004        | Organix Chemistry Solutions LLC |
| Compounds with high monoamine transporter affinity  | 7026516              | 04/11/2006        | Organix Chemistry Solutions LLC |
| Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level  | 7081238              | 07/25/2006        | Organix Chemistry Solutions LLC |
| Vasoconstrictor cannabinoid analogs   | 7109245              | 09/19/2006        | Organix Chemistry Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport   | 7199132              | 04/03/2007        | Organix Chemistry Solutions LLC |



|  |         |            |                                       |
|--|---------|------------|---------------------------------------|
| Cannabinoids   | 7285687 | 10/23/2007 | Organix<br>Chemistry<br>Solutions LLC |
| Tropane Compounds  | 7476740 | 01/13/2009 | Organix<br>Chemistry<br>Solutions LLC |
| Therapeutic compounds  | 7439264 | 10/21/2008 | Organix<br>Chemistry<br>Solutions LLC |
| Method of Material Processing to produce a fiber product   | 7553419 | 06/30/2009 | Organix<br>Chemistry<br>Solutions LLC |
| VMAT inhibitory compounds  | 9546151 | 11/29/206  | Organix<br>Chemistry<br>Solutions LLC |
| Inflammation Therapy   | 9763894 | 09/19/2017 | Organix<br>Chemistry<br>Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport  |         |            | Organix<br>Chemistry<br>Solutions LLC |
| Substituted 2-carboxyalkyl-3 (fluorophenyl)-8-(3-halopropen-2-yl) nortropans and their use as imaging agents for neurodegenerative disorders | 5853696 | 12/29/1998 | Organix<br>Chemistry<br>Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport  | 6353105 | 03/05/2002 | Organix<br>Chemistry<br>Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport  | 6417221 | 07/09/2002 | Organix<br>Chemistry<br>Solutions LLC |
| Dopamine transporter imaging agents  | 6548041 | 04/15/2003 | Organix<br>Chemistry<br>Solutions LLC |
| Tropane analogs and methods for inhibition of monoamine transport  | 6670375 | 12/30/2003 | Organix<br>Chemistry<br>Solutions LLC |
| Boat tropanes  | 7105678 | 09/12/2006 | Organix<br>Chemistry<br>Solutions LLC |
| Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level   | 7553478 | 06/30/2009 | Organix<br>Chemistry<br>Solutions LLC |

**Patent Applications**

N/A

**SCHEDULE 2**

**TRADEMARKS**

**Trademark Registrations**

| <b>Mark</b> | <b>Registration Number</b> | <b>Registration Date</b> | <b>Record Owner</b>             |
|-------------|----------------------------|--------------------------|---------------------------------|
| Powerplant  | 86768762                   | 9/25/2015                | Organix Chemistry Solutions LLC |
| Repect      | 3931304                    | 3/15/2011                | Organix Chemistry Solutions LLC |

**Trademark Applications**

N/A

**SCHEDULE 3**

**COPYRIGHTS**

N/A